Dr. Michael I. Lewis, MD

Dr. Lewis practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Lewis' NPI, 1801824941, was assigned on June 29, 2006. Dr. Lewis graduated from University of the Witwatersrand in 1974. Dr. Lewis holds California license A42166.

Dr. Lewis' primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Lewis' primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. The medical group on file is Cedars-Sinai Medical Group. Dmand AI also links Dr. Lewis to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lewis practices. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Lewis' primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Lewis is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Lewis' licenses on file in 2 states: California and West Virginia.

Dmand AI lists chronic lung disease, pneumonia and pulmonary heart disease among the conditions Dr. Lewis treats.

CMS data shows 255 Medicare services from Dr. Lewis across 7 procedure codes in 2024, for 70 Medicare patients. Medicare paid $21,445 for them.

CMS counts 70 Medicare patients who saw Dr. Lewis in 2024. The largest group is 65 to 74, with 27 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 53% are also on Medicaid. Their average risk score is 3.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lewis' median patient age at 61, with 46% women.

In 2024, Dr. Lewis wrote 153 Medicare Part D claims for 12 patients. 29% of them were for generic drugs. CMS names the drug for 139 of them, across 7 drugs with 11 or more claims each, at $2,039,195 in total drug cost. In 2023, CMS named 169 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Lewis for performance year 2024, reported as part of a group. Dr. Lewis accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 15 papers to Dr. Lewis, published from 2005 to 2018. 2018 was the busiest year, with 2. The most frequent topics are Antibodies, Bacterial, Immunoglobulin M and Scrub Typhus. Dr. Lewis' most frequent co-authors are Michael Lewis, DO, Robert K. Chua, MD and Colin MacDonald Court, MD.

Dmand AI links Dr. Lewis to 1 clinical trial. Conditions studied include Pulmonary Arterial Hypertension and Hypertension, Pulmonary.

CMS Open Payments shows 19 general payments to Dr. Lewis from 10 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 95% of the total. Ipsen Biopharmaceuticals, Inc paid the most, $273.

Dr. Lewis graduated from University of the Witwatersrand in 1974.

Dr. Lewis is in network with 6 carriers, including Blue Cross Blue Shield of Michigan, Blue Cross Blue Shield of Massachusetts and HCSC. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.